---
reference_id: "PMID:33755621"
title: New Adjuvant Drug for Lung Cancer.
authors:
- Aschenbrenner DS
journal: Am J Nurs
year: '2021'
doi: 10.1097/01.NAJ.0000742492.40886.52
content_type: abstract_only
---

# New Adjuvant Drug for Lung Cancer.
**Authors:** Aschenbrenner DS
**Journal:** Am J Nurs (2021)
**DOI:** [10.1097/01.NAJ.0000742492.40886.52](https://doi.org/10.1097/01.NAJ.0000742492.40886.52)

## Content

1. Am J Nurs. 2021 Apr 1;121(4):23-24. doi: 10.1097/01.NAJ.0000742492.40886.52.

New Adjuvant Drug for Lung Cancer.

Aschenbrenner DS(1).

Author information:
(1)Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland 
University in Baltimore. She also coordinates Drug Watch : 
daschenbrenner@ndm.edu .

A new adjuvant treatment, osimertinib (Tagrisso), has been approved for patients 
with non-small cell lung cancer whose tumors have certain mutations.The most 
common adverse effects of treatment are leukopenia, lymphopenia, 
thrombocytopenia, diarrhea, anemia, rash, musculoskeletal pain, nail toxicity, 
neutropenia, dry skin, stomatitis, fatigue, and cough.

Copyright Â© 2021 Wolters Kluwer Health, Inc. All rights reserved.

DOI: 10.1097/01.NAJ.0000742492.40886.52
PMID: 33755621 [Indexed for MEDLINE]